Meeting high expectations
In the case of filgotinib, side effects are similar to or less severe than those seen in patients receiving other medications or placebos. Over the last few years, Galapagos published test results obtained with smaller patient groups. But now, larger groups of patients have also been tested and the results finalized. With these now made public, the biggest steps towards regulatory approval have been taken.